News | November 07, 2025
Pfizer reports Q3 vaccine sales decline amid challenging US market conditions
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Subscribe To Our Newsletter & Stay Updated
